Literature DB >> 28095749

Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.

Sonali S Patel1, Uyen Truong1, Martina King2, Annie Ferland2, Kerrie L Moreau3,4, Jennifer Dorosz5, John E Hokanson6, Hong Wang6, Gregory L Kinney6, David M Maahs7, Robert H Eckel2, Kristen J Nadeau7,8,9, Melanie Cree-Green7,8,9.   

Abstract

Women with polycystic ovarian syndrome (PCOS) have evidence of subclinical cardiovascular disease (CVD). However, insulin resistance, an important factor in the development of CVD in adults, is common in adolescents with PCOS, yet data in adolescents are limited. Therefore, we sought to measure insulin resistance and CVD markers in obese youth with and without PCOS. Thirty-six PCOS and 17 non-PCOS adolescent girls who were obese, sedentary, and non-hypertensive were recruited from clinics located within the Children's Hospital Colorado. Following 3 days of controlled diet and restricted exercise, fasting plasma samples were obtained prior to a hyperinsulinemic euglycemic clamp. PCOS girls were more insulin resistant than controls (glucose infusion rate 5.24±1.86 mg/kg/min vs 9.10±2.69; p<0.001). Girls with PCOS had blood pressure in the normal range, but had greater carotid intima-media thickness (cIMT) (0.49±0.07 mm vs 0.44±0.06; p=0.038), beta stiffness index (5.1±1.3 U vs 4.4±0.9; p=0.037), and reduced arterial compliance (1.95±0.47 mm2/mmHg × 10-1 vs 2.13±0.43; p=0.047). PCOS girls had a normal mean lipid profile, yet had a more atherogenic lipoprotein cholesterol distribution and had persistent elevations of free fatty acids despite hyperinsulinemia (68±28 μmol/mL vs 41±10; p=0.001), both potential contributors to CVD. Free fatty acid concentrations correlated best with all CVD markers. In summary, adolescent girls with PCOS have greater cIMT and stiffer arteries than girls without PCOS, perhaps related to altered lipid metabolism, even when clinical measures of blood pressure and cholesterol profiles are 'normal'. Therefore, management of adolescent PCOS should include assessment of CVD risk factor development.

Entities:  

Keywords:  carotid intima–media thickness; cholesterol; obesity; pediatrics; polycystic ovarian syndrome; risk factors

Mesh:

Substances:

Year:  2017        PMID: 28095749      PMCID: PMC5901904          DOI: 10.1177/1358863X16682107

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  75 in total

1.  Low sex hormone-binding globulin is associated with low high-density lipoprotein cholesterol and metabolic syndrome in women with PCOS.

Authors:  Mei-Jou Chen; Wei-Shiung Yang; Jehn-Hsiahn Yang; Chuhsing Kate Hsiao; Yu-Shih Yang; Hong-Nerng Ho
Journal:  Hum Reprod       Date:  2006-06-06       Impact factor: 6.918

2.  Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.

Authors:  C Meyer; B P McGrath; H J Teede
Journal:  J Clin Endocrinol Metab       Date:  2005-07-26       Impact factor: 5.958

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 4.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

5.  Influence of insulin resistance and body mass index at age 13 on systolic blood pressure, triglycerides, and high-density lipoprotein cholesterol at age 19.

Authors:  Alan R Sinaiko; Julia Steinberger; Antoinette Moran; Ching-Ping Hong; Ronald J Prineas; David R Jacobs
Journal:  Hypertension       Date:  2006-08-21       Impact factor: 10.190

6.  Relationship between androgen levels and blood pressure in young women with polycystic ovary syndrome.

Authors:  Mei-Jou Chen; Wei-Shiung Yang; Jehn-Hsiahn Yang; Chi-Ling Chen; Hong-Nerng Ho; Yu-Shih Yang
Journal:  Hypertension       Date:  2007-03-26       Impact factor: 10.190

7.  Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  R A Wild; P C Painter; P B Coulson; K B Carruth; G B Ranney
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

8.  Androgens augment proximal tubule transport.

Authors:  Albert Quan; Sumana Chakravarty; Jian-Kang Chen; Jian-Chun Chen; Samer Loleh; Neel Saini; Ray C Harris; Jorge Capdevila; Raymond Quigley
Journal:  Am J Physiol Renal Physiol       Date:  2004-04-20

9.  The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.

Authors:  Francesco Orio; Stefano Palomba; Letizia Spinelli; Teresa Cascella; Libuse Tauchmanovà; Fulvio Zullo; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

10.  Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.

Authors:  J Q Purnell; J E Hokanson; S M Marcovina; M W Steffes; P A Cleary; J D Brunzell
Journal:  JAMA       Date:  1998-07-08       Impact factor: 157.335

View more
  19 in total

1.  Alterations in plasma non-esterified fatty acid (NEFA) kinetics and relationship with insulin resistance in polycystic ovary syndrome.

Authors:  Uche Ezeh; Zorayr Arzumanyan; Daria Lizneva; Ruchi Mathur; Yen-Hao Chen; Raymond C Boston; Y-D Ida Chen; Ricardo Azziz
Journal:  Hum Reprod       Date:  2019-02-01       Impact factor: 6.918

2.  Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus.

Authors:  Petter Bjornstad; Michal Schäfer; Uyen Truong; Melanie Cree-Green; Laura Pyle; Amy Baumgartner; Yesenia Garcia Reyes; Aristides Maniatis; Sunil Nayak; R Paul Wadwa; Lorna P Browne; Jane E B Reusch; Kristen J Nadeau
Journal:  Circulation       Date:  2018-12-18       Impact factor: 29.690

Review 3.  Cardiometabolic risk in obese children.

Authors:  Stephanie T Chung; Anthony U Onuzuruike; Sheela N Magge
Journal:  Ann N Y Acad Sci       Date:  2018-01       Impact factor: 5.691

4.  Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.

Authors:  M Kupreeva; A Diane; R Lehner; R Watts; M Ghosh; S Proctor; D Vine
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

5.  Serum-Derived Exosomal microRNAs in Lipid Metabolism in Polycystic Ovary Syndrome.

Authors:  Yanli Hong; Jiayun Wu; Simin Yu; Miao Hui; Sipei Lin
Journal:  Reprod Sci       Date:  2022-08-03       Impact factor: 2.924

6.  Using simple clinical measures to predict insulin resistance or hyperglycemia in girls with polycystic ovarian syndrome.

Authors:  Melanie Cree-Green; Ninghe Cai; Jessica E Thurston; Gregory V Coe; Lindsay Newnes; Yesenia Garcia-Reyes; Amy D Baumgartner; Laura Pyle; Kristen J Nadeau
Journal:  Pediatr Diabetes       Date:  2018-10-09       Impact factor: 4.866

7.  Poor Sleep Is Related to Metabolic Syndrome Severity in Adolescents With PCOS and Obesity.

Authors:  Stacey Simon; Haseeb Rahat; Anne-Marie Carreau; Yesenia Garcia-Reyes; Ann Halbower; Laura Pyle; Kristen J Nadeau; Melanie Cree-Green
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

8.  Editoral commentary: Understanding cardiovascular disease risk in women with polycystic ovary syndrome.

Authors:  Melanie Cree-Green
Journal:  Trends Cardiovasc Med       Date:  2019-09-24       Impact factor: 6.677

9.  Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity.

Authors:  Julia Hudnut-Beumler; Jill L Kaar; Anya Taylor; Megan M Kelsey; Kristen J Nadeau; Philip Zeitler; Janet Snell-Bergeon; Laura Pyle; Melanie Cree-Green
Journal:  Pediatr Diabetes       Date:  2021-04-27       Impact factor: 3.409

10.  Pathogenesis of Reproductive and Metabolic PCOS Traits in a Mouse Model.

Authors:  Valentina Rodriguez Paris; Melissa C Edwards; Ali Aflatounian; Michael J Bertoldo; William L Ledger; David J Handelsman; Robert B Gilchrist; Kirsty A Walters
Journal:  J Endocr Soc       Date:  2021-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.